Medication for COVID-19 Exposure and Possible Infection
For individuals exposed to SARS-CoV-2 who are at high risk for severe COVID-19 (unvaccinated, vaccine non-responders, or severely immunocompromised), post-exposure prophylaxis with anti-SARS-CoV-2 monoclonal antibodies is recommended. 1
Post-Exposure Prophylaxis Strategy
High-Risk Patients Requiring Prophylaxis
Post-exposure prophylaxis should be prioritized for:
- Patients with haematological malignancies
- Hematopoietic stem cell transplant recipients
- Severely immunocompromised individuals
- Vaccine non-responders or those not expected to respond to vaccination
- Unvaccinated high-risk patients
The evidence strongly supports anti-SARS-CoV-2 monoclonal antibodies as post-exposure prophylaxis in these populations 1, though availability and viral variant susceptibility must be considered.
Critical Caveat on Monoclonal Antibodies
Tixagevimab-cilgavimab should NOT be used for prophylaxis given current evidence showing lack of neutralization efficacy against circulating Omicron sub-lineages 2. This represents a major limitation, as prophylactic monoclonal antibodies must demonstrate in vitro neutralization activity against the specific circulating variants in your region.
Treatment for Confirmed or Suspected Early Infection
First-Line Treatment: Nirmatrelvir/Ritonavir
If COVID-19 infection is confirmed or highly suspected within 5 days of symptom onset, nirmatrelvir/ritonavir (Paxlovid) is the preferred antiviral treatment for high-risk patients. 3, 1, 4, 5
This recommendation is based on:
- 88% relative risk reduction in hospitalizations and death 5
- Superior efficacy compared to molnupiravir 3
- Oral administration for 5 days
- Must be started within 5 days of symptom onset
Critical drug interaction warning: Nirmatrelvir/ritonavir has extensive CYP3A4 interactions that may preclude its use in patients on certain medications 3, 5, 6. Review all concurrent medications before prescribing.
Second-Line Treatment: Molnupiravir
Use molnupiravir only when nirmatrelvir/ritonavir is contraindicated or unavailable 3, 1. While it reduces hospitalizations (30% relative risk reduction), it has significant safety concerns:
Absolute contraindications for molnupiravir:
- Pregnancy (causes embryo-fetal lethality and teratogenicity in animal studies) 3
- Breastfeeding 3
- Children (impacts growth plate thickness and bone formation) 3
Special precautions:
- Women of childbearing potential: Use reliable contraception during treatment and for 4 days after last dose 3
- Men planning to conceive: Use contraception during treatment and for 3 months after last dose due to potential genotoxic effects on sperm 3
- Younger adults: Avoid use in those not at high risk due to unknown long-term genotoxicity risk 3
Dosing: 800 mg orally every 12 hours for 5 days, started within 5 days of symptom onset 3
Third-Line Option: Remdesivir
Remdesivir may be considered when oral antivirals are unsuitable, though it requires intravenous administration 1, 7. Use 5 days for moderate disease without mechanical ventilation, consider extending to 10 days for severe disease requiring mechanical ventilation 7.
Testing and Timing Considerations
Testing is essential: Patients exposed to SARS-CoV-2 should be tested using molecular NAT assays targeting at least two distinct viral gene sequences 1. Rapid antigen tests can be used for point-of-care diagnosis but should be confirmed by molecular testing 1.
The 5-day window is critical: All antiviral treatments are most effective when started within 5 days of symptom onset 3, 1, 7, 6. This requires rapid access to testing and treatment infrastructure.
For Standard-Risk Patients
For patients without high-risk features who are exposed or have mild COVID-19, no specific antiviral prophylaxis or treatment is recommended 8, 9. These individuals should follow standard preventive measures including hand hygiene, masking, and isolation 1.
What NOT to Use
Hydroxychloroquine should NOT be used for prophylaxis or treatment at any stage—it provides no benefit and increases adverse effects 8, 2. This is a strong recommendation based on high-certainty evidence 2.